Articles

Emotional resilience is a key factor in mitigating the effects of compassion fatigue, which is a common result of carrying the emotional weight of the job nearly 24-7. Emotional resilience involves adapting to this stress by developing coping strategies and strong support systems. Read More ›

Working in healthcare is widely recognized as a highly stressful profession. Caseloads can be overwhelming, and staff resources sometimes fall short. Navigators engage with patients facing stressful, life-changing circumstances, serving as a haven for patients to process a diagnosis, confront challenges and setbacks, and digest difficult news. Read More ›

In the ever-evolving field of oncology, the efficient management of therapy side effects is crucial for improving patient quality of life and any potential treatment outcomes. Join us as we explore 3 clinical studies that shed new light on innovative approaches to managing side effects in patients with cancer.

Read More ›

There’s been a great deal of talk about integrating palliative care into oncology; it was even the theme of the Presidential Address by Lynn Schuchter, MD, at ASCO 2024. But how and when should that integration occur?

Read More ›

As we dive into the first issue of The Oncology Nurse-APN/PA for the new year, I find myself reflecting on the ever-evolving landscape of cancer care and the indispensable role we play in it. Your unwavering commitment to patient care is the cornerstone of the oncology field, and I want to take a moment to acknowledge and celebrate your invaluable contributions. Read More ›

No one likes to watch their investments lose money, but downward market volatility can feel particularly scary for people who plan to retire in the near future. Their anxiety is understandable. They’ve spent their careers building their nest eggs and now—at a time when they plan to give up their income-producing jobs—they face the prospect of living off less money than they had envisioned.

Read More ›

Polycythemia vera was first recognized by French physician Louis H. Vaquez in 1892 and was known then as maladie de Vaquez. The name poly-cyt-[h]emia originates from the Greek and Latin, and literally means many-cells-in the blood.

Read More ›

This article summarizes 2 analyses from the phase 3 GMMG-HD7 trial presented at ASH 2024, as well as the FDA’s Oncologic Drugs Advisory Committee support for the use of minimal residual disease as an accelerated approval endpoint in multiple myeloma clinical trials. Read More ›

In this article, the results from 2 studies of Isa-KRd in newly diagnosed multiple myeloma (NDMM) are summarized, with the GMMG-CONCEPT trial focusing on high-risk NDMM and the IFM 2020-02 MIDAS study focusing on transplant-eligible NDMM. Read More ›

This article summarizes a post-hoc analysis of data from the MASTER study and the GRIFFIN study of patients with newly diagnosed multiple myeloma with high-risk cytogenetic abnormalities. Read More ›

Page 4 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: